TYK Medicines, Inc.

2410 · HKEX

Public Market Listing

2410HKEX

HKEX primary exchange listing

Live quotes, historical charts, and market capitalization for TYK Medicines, Inc. are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(1 total)
1Total Assets
0Approved
1Phase 3 / Filed
0Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Phase 3
EGFRSmall molecule
Non-Small Cell Lung Cancer

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
December 2027 (1)
AsandeutertinibPhase 2NSCLC
Est. primary completion 2027-12-01 · NCT06672068 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

6 February 2026Filing acceptedAsandeutertinib (TY-9591)NMPA accepts the asandeutertinib (TY-9591) NDA for first-line EGFR-mutated locally advanced or metastatic NSCLC
CN, NMPA · TYK Medicines, Inc. · Source ↗

Financial reports

Quarterly & interim (2)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-H1—$12M—$16Mreport ↗

TYK Medicines, Inc. reported R&D spend of $12.25M, down 36.0% YoY and a quarterly net burn of $15.74M for H1 2025.

Figures only: this period's report disclosed no narrative text

View 1 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-H1—$19M—$31Mreport ↗

Annual history (2 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY—$34M——report ↗
View 1 more year
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY—$33M—$54Mreport ↗